TAIZHOU, China, June 27, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. is pleased to ann...
TAIZHOU, China, May 5, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", toge...
TAIZHOU, China, April 13, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", t...
TAIZHOU, China, April 11, 2022 /PRNewswire/ -- The board of directors of Jiangsu Recbio Technology ...
Offer Price of HK $24.80 per H Share To Raise Proceeds Up to HK$765 Million Focus on the R&D of HP...
TAIZHOU, China, Feb. 15, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (Recbio), aChina...
* Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III ...
TAIZHOU, China, Nov. 17, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a bio...
* Well tolerated and good safety profile, no SAE or TEAE leading to early discontinuation, no abn...
TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biop...